Learn more about FDA-approved AURYXIA® (ferric citrate), iron deficiency anemia (IDA) and hyperphosphatemia (HP). Important Safety Information | Full Prescribing Information | AkebiaCares For Healthcare Professionals

2024年2月18日 · Auryxia: side effects, dosage, interactions, FAQs, reviews. Used for: hyperphosphatemia of renal failure, iron deficiency anemia

Find patient medical information for Auryxia oral on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings.

Choose the indication you are prescribing for and learn what AURYXIA can do for your patients. Read Important Safety Information and Prescribing Information on this page.

2024年2月5日 · Auryxia (ferric citrate) is a phosphate binder used for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis. What Are Side Effects of Auryxia? Common side effects of Auryxia include: dark stools (related to the iron content). Seek medical care or call 911 at once if you have the following serious side effects:

2024年12月4日 · Detailed dosage guidelines and administration information for Auryxia (ferric citrate). Includes dose adjustments, warnings and precautions.

Learn more about AURYXIA® (ferric citrate). A prescription medication for adults with hyperphosphatemia in CKD on dialysis. Important Safety Information | Full Prescribing Information | AkebiaCares

2025年1月7日 · Auryxia (ferric citrate) is a phosphate binder used to treat high phosphorus levels (hyperphosphatemia) in adults with chronic kidney disease (CKD) on dialysis. It's also used as an iron supplement to treat iron-deficiency anemia (IDA) in adults with CKD who aren't on dialysis.

AURYXIA is a prescription medicine that can lower the amount of phosphate in the blood for adults with chronic kidney disease (CKD) who ARE on dialysis. Who should not take AURYXIA? Do not take AURYXIA if you have been diagnosed with an iron overload syndrome, such as hemochromatosis. AURYXIA may not be right for you.

2025年1月8日 · Auryxia is an iron replacement product indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis. (1) Adjust dose by 1 to 2 tablets as needed to maintain serum phosphorus at target levels, up to a maximum of 12 tablets daily. Dose can be titrated at 1-week or longer intervals. (2.1)